Browse the evidence

Gene targeting of GPR75 is more effective than current pharmacologic therapies without the known side effects.

Gene targeting may provide a safer and more effective alternative to current obesity treatments.

GPR75 and its ligand promote hypertension, inflammation, obesity, and insulin resistance.

Understanding the role of GPR75 can inform strategies to mitigate obesity-related health risks.

The annual additional direct medical cost for Semaglutide was USD 4,086.82.

Practitioners should consider the high cost of Semaglutide when discussing treatment options.

Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.

Reducing the cost of semaglutide could enhance its affordability and accessibility for patients.

Semaglutide is projected to increase annual health care spending by $23 billion.

Healthcare systems should prepare for increased spending associated with the adoption of semaglutide.

The application of injectable agents is hindered by adverse effects, high costs, and accessibility issues.

Practitioners should consider these barriers when recommending injectable therapies for obesity.

Future pharmacotherapeutic options, including combination therapies and gene therapy, may improve outcomes for patients with genetic obesity disorders.

Practitioners should stay informed about emerging therapies that may enhance treatment for genetic obesity.

Health care expenditures increased by $80 per month during the 13- to 24-month period, excluding the cost of semaglutide.

Practitioners should consider potential increases in health care costs when prescribing semaglutide.

The healthcare situation for people with obesity in Germany is deficient.

Healthcare providers should recognize the deficiencies in the current obesity care system.

There were previously no legal frameworks for guideline-based care for people with obesity.

Legislators need to establish legal frameworks to support guideline-based obesity care.

Carbon monoxide (CO) has potential therapeutic applications in obesity treatment.

Practitioners might explore CO-based therapies as innovative options for obesity management.

HEC-CG115 has an optimal safety profile with a no observed adverse effect level of 3 mg/kg.

HEC-CG115 appears to be a safe option for therapeutic use.

Obesity is a chronic metabolic disorder that shares underlying pathophysiology with type 2 diabetes mellitus, cardiovascular disease, and diabetic cardiomyopathy.

Understanding the metabolic links can help in developing targeted interventions for obesity and related diseases.

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

Ingestion of 20 g and 40 g of soy protein isolate does not stimulate increased rates of myofibrillar protein synthesis (MPS) under resting conditions in the elderly.

Soy protein isolate may not be effective for increasing muscle protein synthesis in elderly individuals.

There was no significant effect of the intervention on daily steps, daily activity energy expenditure, or moderate-to-vigorous physical activity compared to the control group.

Practitioners should note that the program did not significantly increase physical activity levels.

There were no differences in anthropometric variables after the intervention period with strength training.

Strength training may not lead to changes in body composition metrics in this population.

Infertility affects up to 17.5% of the global population.

Awareness of the prevalence of infertility can guide public health initiatives.

The USDA withdrew its Eating Right Pyramid due to pressure from meat and dairy lobbying groups.

Practitioners should be aware of the influence of food lobbying on dietary guidelines.

Body and fat mass and blood glucose levels are not regulated, controlled, or defended.

Practitioners should reconsider the concepts of regulation and control in metabolism when addressing obesity.

The 'Invisible Hand of Metabolism' illustrates unregulated behavior of cells affecting physiological states.

Understanding cellular behavior can help in developing strategies for obesity management.

Sugar-sweetened beverage companies have successfully marketed their products by associating them with global cultural and sporting events.

Awareness of marketing tactics can help consumers make informed choices about beverage consumption.

The BB-Health study will evaluate age-sensitive cognitive assessments and cerebral hemodynamics as outcomes.

Practitioners should monitor cognitive health and cerebral hemodynamics in interventions.

GLP-1 RAs slow both thoracic and abdominal aneurysm growth.

GLP-1 RAs may be beneficial in managing aneurysms in clinical settings.